EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience

Cécile Cussac, Pauline Rivière iD, Romain Altwegg iD, Ludovic Caillo, Florian Poullenot, David Laharie iD, Cyrielle Gilletta, Guillaume Le Cosquer

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70077 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Cécile Cussac und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Pancreatology, Hôpital Rangueil, CHU de Toulouse, Université Toulouse Paul Sabatier, Toulouse, France. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Janus Kinase 1, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicenter retrospective study examines 18 patients with difficult‐to‐treat inflammatory bowel diseases who received advanced combination treatment (ACT) with selective JAK1 inhibitors and biologics, totaling 11.8 patient‐years of exposure. Treatment was discontinued in three patients due to adverse events. At 3 months, 77.8% achieved steroid‐free clinical remission. The infection incidence rate was 25.4 per 100 person‐years (95% CI: 6.47–69.19), though the wide confidence interval limits conclusions on safety differences with monotherapy. These findings highlight the importance of preventive measures, careful patient selection, and rigorous monitoring to mitigate infection risks associated with ACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesJanus Kinase 1Janus Kinase InhibitorsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedDrug Therapy, CombinationTreatment OutcomeAged

Stichwörter der Autor:innen

advance combined treatmentbiologicsdrug safetyinflammatory bowel diseasesselective JAK1 inhibitors

Substanzen

Janus Kinase 1Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology and Pancreatology, Hôpital Rangueil, CHU de Toulouse, Université Toulouse Paul Sabatier, Toulouse, France.
  • Department of Gastroenterology and Hepatology, Centre Médico-Chirurgical Magellan, Hôpital Haut-Lévêque, CHU de Bordeaux, Bordeaux, France.
  • Université de Bordeaux; INSERM CIC 1401, Bordeaux, France.
  • Department of Hepato-Gastroenterology, Hôpital Saint-Eloi, CHU Montpellier, Université de Montpellier, Montpellier, France.
  • Department of Gastroenterology, Nimes University Hospital, Nimes, France.

ORCID-Profile: Pauline Rivière, Romain Altwegg, David Laharie

Zitieren

APA

Cussac, C., Rivière, P., Altwegg, R., Caillo, L., Poullenot, F., Laharie, D., Gilletta, C., & Le Cosquer, G. (2025). Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70077

Vancouver

Cussac C, Rivière P, Altwegg R, Caillo L, Poullenot F, Laharie D, et al. Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70077

BibTeX
@article{Cussac2025,
  author = {Cussac, Cécile and Rivière, Pauline and Altwegg, Romain and Caillo, Ludovic and Poullenot, Florian and Laharie, David and Gilletta, Cyrielle and Le Cosquer, Guillaume},
  title = {Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70077}
}
Kostenlos starten →